Author(s):
Nabil A. Alhemiary, Mohammed A. Helmi
Email(s):
nafarhan@nu.edu.sa
DOI:
10.52711/0974-360X.2025.00511 
Address:
Nabil A. Alhemiary1,2*, Mohammed A. Helmi3
1Department of Chemistry, Faculty of Science and Arts- Sharourah, Najran University, Sharourah, Saudi Arabia.
2Department of Chemistry, Faculty of Science, Ibb University, P.O. Box 70270, Ibb, Yemen.
3Département of Analytical Chemistry, Faculty of Pharmacy, Helwan University, Egypt.
*Corresponding Author
Published In:
Volume - 18,
Issue - 8,
Year - 2025
ABSTRACT:
This aims of study to develop and validate two chromatographic methods that provide a fast, sensitive, and reliable stability-indicating assay for the simultaneous determination of Empagliflozin and Linagliptin in their pure forms, as well as Glyxambi® tablets. The first technique employed was thin-layer chromatography (TLC) utilizing a developing solution composed of ethyl acetate, methanol, and hexane in a ratio of 90:5:5 (v/v/v). The separation of Empagliflozin and Linagliptin was achieved on silica gel plates, with a scanning wavelength at 248 nm. Retention factor (RF) values for Linagliptin was 0.16 and Empagliflozin was 0.51. Mean percentage recoveries were 101.32% (SD 0.942) for Linagliptin and 99.84% (SD 1.426) for Empagliflozin, the linearity across concentration ranges of 5-50µg/band and 10-150µg/band, respectively. The second technique, known as RP-HPLC, separated the samples using a GL Sciences reverse-phase C18 column (250mm x 4.6mm x 5µm). Water, acetonitrile, and 0.05 M phosphate buffer with a pH of 3.8 (45:50:5, v/v/v) made up the mobile phase, which was used for 10min. We carried out UV detection at 248nm. The chromatogram showed the presence of Linagliptin and Empagliflozin, with retention periods of Rt = 2.242min and 4.065min, respectively. Mean percentage recoveries for Linagliptin were 100.81% (SD 1.631) and for Empagliflozin was 101.44% (SD 1.381), A satisfactory resolution was attained, and linearity was established within the range of 0.5-10 and 2-35 µg/ml, respectively. We successfully determined Linagliptin and Empagliflozin, whether in bulk powder or combination dose form (Glyxambi® tablets), quantitatively for the pharmaceutical market using the TLC and RP-HPLC techniques.
Cite this article:
Nabil A. Alhemiary, Mohammed A. Helmi. Simultaneous, Development and Validation Measurement of Empagliflozin and Linagliptin for Glyxambi® Tablets using TLC and RP-HPLC. Research Journal Pharmacy and Technology. 2025;18(8):3549-6. doi: 10.52711/0974-360X.2025.00511
Cite(Electronic):
Nabil A. Alhemiary, Mohammed A. Helmi. Simultaneous, Development and Validation Measurement of Empagliflozin and Linagliptin for Glyxambi® Tablets using TLC and RP-HPLC. Research Journal Pharmacy and Technology. 2025;18(8):3549-6. doi: 10.52711/0974-360X.2025.00511 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-8-14
REFERENCE:
1. Ayoub BM. Emam RM. Youssef MM, El-Kattan MV. Sayed MA. Kowider AM. Seha AH. Rabea EA. Yakout RM. Faried RH. Mean centering method for determination of Empagliflozin and metformin. Marmara Pharm J. 2017; 21: 669–674. doi.org/10.12991/marupj.323590
2. Hailat M. Zakaraya Z. Alani I. Osaid Al Meanazel O. Ramadan Al-Shdefat R. Khalid Answer K. Saadh MJ. Dayyih W. Pharmacokinetics and Bioequivalence of Two Empagliflozin, with Evaluation in Healthy Jordanian Subjects under Fasting and Fed Conditions. Pharmaceuticals. 2022; 15: 0–9. doi.org/10.3390/ph15020193
3. Frampton JE. Empagliflozin: a review in type 2 diabetes. Drugs. 2018; 78: 1037–1048. doi.org/10.1007/s40265-018-0937-z
4. Patil SD. Amurutkar SV. Upasani CD. Development and Validation of Stability Indicating RP-HPLC Method for Empagliflozin. Asian J Pharm Anal. 2016; 6: 201. doi.org/10.5958/2231-5675.2016.00030.2
5. Eswarudu MM. Ouchitya G. Sudhakar Reddy N. Deekshitha M. Srinivasa Babu P. Review on Analytical Methods for Estimation of Antidiabetic Drugs: Empagliflozin, Linagliptin and Metformin Hydrochloride. Asian J Pharm Anal. 2023; 7: 1–10. doi.org/ 10.52711/2231-5675.2023.00007
6. Steven S. Oelze M. Hanf A. Kröller-Schön S. Kashani F. Roohani S. Welschof P. Kopp M. Gödtel-Armbrust U. Xia N. Li H, Schulz E. Lackner KJ. Wojnowski. Bottari SP. Wenzel P. Münzel T. Daiber A. The SGLT-2 inhibitor Empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol 2017; 13: 370–385. doi.org/10.1016/j.redox.2017.06.009
7. Hsia DS. Grove O. Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017; 24. doi.org/10.1097/MED.0000000000000311
8. Sen AK. Pandey H. Maheshwari RA. Aarti Sachin Zanwar AS. Ramaswamy Velmurugan R. Sen AK. Novel UV Spectroscopic Methods for Simultaneous Assessment of Empagliflozin, Linagliptin and Metformin in Ternary Mixture. Indian J Pharm Educ Res. 2022; 56: S669–S681. doi.org 10.5530/ijper.57.2.69
9. Dayyih WA. Hailat M. Al Hujran TA. Spectrophotometric analysis of Empagliflozin tablets as SGLT2 inhibitors in pharmaceutical samples. J Appl Pharm Sci. 2022; 12: 140–146. doi.org/10.7324/JAPS.2022.121015
10. Sher M Bashir S, Fatima A, Fatima A. Qaisar MN. Ul-Hassan MN. (2023) Simultaneous determination of metformin and glipalamide by RP-HPLC in or dispersible tablets and their pharmacokinetic evaluation. Authorea. 2023. doi.org/10.22541/au.168287817.70016512/v1
11. Jaiswal R. Kohad M. Michael PE. Raval H. Development and Validation of Stability Indicating HPTLC Method for Simultaneous Estimation of Metformin Hydrochloride and Remogliflozin Etabonate in Pharmaceutical Dosage Form. Research Square. 2022; 1: 1-18. doi.org/ 10.21203/rs.3.rs-1996215/v1
12. Abu Dayyih W. Zakaraya Z. Hailat M. The Validation and Determination of Empagliflozin Concentration in the Presence of Grapefruit Juice Using HPLC for Pharmacokinetic Applications. Molecules. 2024; 29: 1–12. doi.org/10.3390/molecules29061236
13. Siridevi MP. Kumar HT. Rao SY. Rao VPK. RP-HPLC method for quantification of Empagliflozin in pharmaceutical formulation. Asian J Pharm Technol. 2019; 9: 208–211. doi.org/ 10.5958/2231-5713.2019.00035.7
14. Sharif S. Bashir R. Adnan A. Mansoor S. Ahmad I. Rashid A. Tahir SM. Stability Indicating, pH and pKa Dependent HPLC–DAD Method for the Simultaneous Determination of Weakly Ionizable Empagliflozin, Dapagliflozin and Canagliflozin in Pharmaceutical Formulations. Chromatographia. 2020; 83: 1453–1465. doi.org/10.1007/s10337-020-03962-4
15. Ayoub BM. Mowaka S. LC–MS/MS Determination of Empagliflozin and Metformin. J Chromatogr Sci. 2017; ID: 3726897. Doi.org/10.1093/chromsci/bmx030
16. Jagadeesh M. Kumar G. Development and Validation of Empagliflozin in Human Plasma Using Nevirapine as Internal Standard By Liquid Chromatography-Tandem Mass Spectrometry. Int J Health Sci (Qassim). 2022; 6: 272–281. doi.org/10.53730/ijhs.v6ns6.9683
17. Ayoub B, El Zahar N, Michel H, Tadros M. Economic spectrofluorometric bioanalysis of Empagliflozin in rats’ plasma J Anal Methods Chem; 2021: 9983477
18. Elmasry MS. Hasan MA. Hassan WS. Hassan WS. Merey HA. Nour IN. Fluorometric Study on Antidiabetic Combined Drugs; Empagliflozin and Linagliptin in Their Pharmaceutical Formulation and Human Plasma. Spectro Chim Acta Part A Mol Biomol Spectrosc 248: 119258. doi.org/https://doi.org/10.1016/j.saa.2020.119258
19. Banik S. Karmakar P. Miah MAH. Development And Validation of A UV-Spectrophotometric Method For Determination of Vildagliptin and Linagliptin in Bulk and Pharmaceutical Dosage Forms. Bangladesh Pharm J. 2015; 18: 163–168. doi.org/10.3329/BPJ.V18I2.24316
20. El-Bagary RI. Elkady EF. Ayoub BM. Spectrofluorometric determination of Linagliptin in bulk and in pharmaceutical dosage form. Eur J Chem. 2014; 5: 380–382. doi.org/10.5155/eurjchem.5.2.380-382.845
21. Hanafy A. Mahgoub H. A Validated HPLC Method for the Determination of Linagliptin in Rat Plasma. Application to a Pharmacokinetic Study. J Chromatogr Sci. 2016; 54: 1573–1577. doi.org/10.1093/chromsci/bmw106
22. Alam I. Nadir AS. Qayoom A. Rehana B. Muzna A. Haji M. Green Liquid Chromatographic Method for Simultaneous Determination of Metformin, Linagliptin and Rivaroxaban: Tablet Manufacturing and Application To in-Vitro Dissolution Studies. Microchem J. 2023; 193: 109025. doi.org/10.1016/j.microc.2023.109025
23. Vijaya K S. Anusha M. Ravinder Reddy S. A Rapid RP-HPLC Method development and Validation for the Analysis of Linagliptinin Bulk and Pharmaceutical Dosage Form. Asian J. Pharm. Ana. 2015; 5(1): 16-20. doi.org/10.5958/2231-5675.2015.00003.4
24. Nannaware PS. Siddheshwar SS. Kolhe MH. A review on analytical methods for estimation of linagliptin in bulk and tablet dosage form, Research Journal of Science and Technology. 2021; 13(2): 127-132. Doi.org/10.52711/2349-2988.2021.00019
25. Shafi MSS. Begum A. Saradhi N. Bioanalytical Method Development and Validation of Entrectinib in Rat Plasma By Liquid Chromatography–Tandem Mass Spectrometry. Asian J Pharm Clin Res. 2020; 13(11). 155-163. doi.org/10.22159/ajpcr.2020.v13i11.39005
26. Moussa BA. Mahrouse MA. Fawzy MG. (2019) A validated LC-MS/MS method For Simultaneous Determination of Linagliptin and Metformin in Spiked Human Plasma Coupled with Solid Phase Extraction: Application to A Pharmacokinetic Study in Healthy Volunteers. Asian J Pharma Clin Res. 2020; 163: 153–161. doi.org/10.22159/ajpcr.2020.v13i11.39005
27. Gahlan AA. Haredy AM. Derayea SM. A Glassy Carbon Electrode for the Determination of Linagliptin, an Antidiabetic Drug in Pure Form, Tablets and Some Biological Fluids by Adsorptive Stripping Voltammetry. Curr Pharm Des 2021; 27:2415–2424. Doi.org/10.2174/1381612826666200925123245
28. Ateş AK. Çelikkan H. Erk N. (2021) Voltammetric determination of Linagliptin in bulk and plasma sample using an electrochemical sensor based on L-cysteine modified 1T-MoS2 nanosheets. Microchem J. 2021; 167: 106308. doi.org/10.1016/j.microc.2021.106308
29. Mai X. Pham T. Le T. Nguyen BT. Thi Nguyen NV. Jong-Seong Kang JS. Mar W. 4, Kim KH. A Capillary Electrophoresis Method for The Determination of The Linagliptin Enantiomeric Impurity. J Sep Sci. 2020; 43: 4480–4487. doi.org/10.1002/jssc.202000493
30. Kamal AH. Hammad SF. Salim M, Elkhodary MM. Marie AA. Simultaneous estimation of two anti-diabetic drugs; Linagliptin and empagliflozin in their tablet by chemometric spectrophotometry. Spectrochimica Acta Part A - Molecular and Biomolecular Spectroscopy. 2023; 305: 12356. doi.org/10.1016/j.saa.2023.123556
31. Vankalapati KV. Pallavi Alegete P. Boodida S. Stability-Indicating Ultra Performance Liquid Chromatography Method Development and Validation For Simultaneous Estimation of Metformin, Linagliptin, and Empagliflozin in Bulk and Pharmaceutical Dosage Form. Biomedical Chromatography. 2021; 35: e501. doi.org/10.1002/bmc.5019
32. Hazarathaiah YC, Mallibabu A. RP-LC Method in Gradient mode for Combined Quantification of Metformin, Linagliptin, and Empagliflozin in Combination Tablets. J Med Chem Sci. 2022; 5: 1018–1025. doi.org/10.26655/JMCHEMSCI.2022.6.15
33. Ayoub AM. UPLC Simultaneous Determination of Empagliflozin, Linagliptin and Metformin. Biomed Chromatogr, RSC Adv. 2015; 25: 95703-95709. doi.org/10.1039/C5RA17231D
34. Baokar S. Patil R. Pandey AN. (2024) Analytical Method Development and Validation of Biguanide, Empagliflozin, and Linagliptin by RP HPLC. Int J Sci Res Chemi. 2024; 9 (7): 285-291. doi.org/10.32628/IJSRCH
35. Siddiqui JF. Ahmed A. Anjum L. Tahreem N. Banu S. Unnisa S. (2023) Analytical Method Development and Validation for Simultaneous Estimation of Empagliflozin and Linagliptin in Bulk Drug and in Pharmaceutical Dosage Formulation by HPLC. Int J Pharm Sci Rev Res. 2023; 81(1): 147-151. doi.org/10.47583/ijpsrr.2023.v81i01.025
36. Borman P. Elder D. Q2 (R1) Validation of Analytical Procedures: Text and Methodology. ICH Qual Guidel an Implement Guid. 2017; 127–166.
37. Mounika PS. Hemant TK. Srinivasa YR. Vara Prasad KR. RP-HPLC Method for Quantification of Empagliflozin in Pharmaceutical Formulation. Asian J. Pharm. Tech. 2019; 9(3): 208-211. dio.org/ 10.5958/2231-5713.2019.00035.7
38. Sahoo MR, Varrier RR, Anithakumari R, Palanichamy G. Bala Sundari BT. Guru B. Analytical Profiling of Saffron (Crocus sativus) using 1H-NMR and FTIR based Metabolomics approach and UV-Vis, HPTLC and TLC Chromatography Fingerprinting. Research Journal of Pharmacognosy and Phytochemistry. 2023; 15(3): 191-7. dio.org/ 10.52711/0975-4385.2023.00029
39. Vyas AJ. Parmar DU. Patel AB. Patel AI, Dudhrejiya AV. Shah SR. Strategic approach for HPLC Method Development and Validation: Review. Asian Journal of Research in Pharmaceutical Sciences. Sci. 2024; 14(1): 71-6. doi.org/10.52711/2231-5659.2024.00011
40. Rana K. Sharma P. Analytical Method Development and Validation for the Simultaneous Estimation of Metformin Hydrochloride and Alogliptin by RP-HPLC in Bulk and Tablet Dosage Forms. Research Journal of Science and Technology. 2021; 13(2): 111-8. dio.org/10.52711/2349-2988.2021.00017
41. Attimarad M. Mueen AKK. Aldhubaib BE. Harsha S. (2011) High-performance Thin Layer Chromatography: A Powerful Analytical Technique in Pharmaceutical Drug Discovery. Pharm Methods. 2011; 2: 71–75. doi.org/10.4103/2229-4708.84436
42. Dagron S. Die International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Handb Ethik und R der Forsch am Menschen. 2014; 541–545. doi.org/10.1007/978-3-642-35099-3_86
43. Pharmacopeia US. The United States Pharmacopeia: USP 30; The National formulary: NF 25, United States Pharmacopeial Convention, Rockville, MD. 2006.
44. El Sheikh R, S Hassan W, Youssef E, Hamdi AY. Badahdah NA. Alzuhiri ME. Gouda AA. (2020) Development and Validation of Rapid Stability-Indicating High-Performance Liquid Chromatography Method for The Determination of Linagliptin and Empagliflozin in Pure and Dosage Forms. Asian J Pharm Clin Res. 2020; 13: 172–177. doi.org/10.22159/ajpcr.2020.v13i4.36939
45. Greenland S. Senn SJ. Rothman KJ. Carlin JB. Poole C. Goodman SN. Altman DG. Statistical Tests, P Values, Confidence Intervals, and Power: A Guide to Misinterpretations. Eur J Epidemiol. 2016; 31: 337–350. doi.org/10.1007/s10654-016-0149-3.